节点文献
脂肪酸合成酶在卵巢癌组织中的表达及意义
Expression and Clinical Significance of Fatty Acid Synthase in Ovarian Cancer
【作者】 孔燕;
【导师】 姜洁;
【作者基本信息】 山东大学 , 妇产科学, 2011, 硕士
【摘要】 研究背景卵巢癌是女性生殖器官最常见的三大恶性肿瘤之一,其发病率仅次于子宫颈癌和子宫体癌而列居第三位,其病死率却占妇科恶性肿瘤之首。到目前为止,据国内外临床资料统计,其五年生存率仅为25%-30%。肿瘤组织的恶性行为与其特殊的物质代谢和能量代谢有着密切的关联。脂肪酸在细胞的能量代谢和结构及其功能上具有重要的作用。脂肪酸合成酶(FASN)是内源性脂肪酸合成的关键酶,因此近年来关于该酶在恶性肿瘤中的表达成为研究的热点之一。为了寻找卵巢癌的早期诊断的有效指标,我们采用免疫组化SP法探讨其在卵巢癌中的表达及临床意义。目的检测脂肪酸合成酶在正常卵巢组织、卵巢良性肿瘤、交界性肿瘤、卵巢癌中的表达情况,探讨它与卵巢癌的相关性,寻找早期诊断及监测预后的生物学指标。方法采用免疫组化SP法检测脂肪酸合成酶在13例正常卵巢组织、13例卵巢良性肿瘤、13例交界性肿瘤以及56例卵巢癌组织中的表达情况,并进行统计学分析(以P<0.05作为检验标准),比较在四种不同的卵巢组织中的表达差异。结果1.脂肪酸合成酶在正常卵巢组织中不表达,而在卵巢良性肿瘤、交界性肿瘤和恶性肿瘤中均有表达,其阳性表达率分别为15.4%、30.8%、67.1%,呈逐步上升趋势。2.在正常组与交界组、正常组与恶性组,恶性组与良性组、恶性组与交界组之间比较,其表达差异有统计学意义(P<0.05);而正常组与良性组、良性组与交界组相比,差异无统计学意义(P>0.05)。3.FASN在卵巢癌中的表达在年龄、分化程度、有无淋巴结转移、腹水细胞学检查各组之间比较无明显差异;而在恶性肿瘤的临床分期之间比较,差异有统计学意义(P<0.05)。4.在卵巢癌患者生存相关性分析中,阳性表达者5年存活率明显低于阴性表达者,两者之间差异有统计学意义(P<0.05)。结论1.在卵巢正常组织、良性肿瘤、交界性肿瘤和恶性肿中,FASN的阳性表达率呈逐步上升趋势,提示卵巢癌的发生、发展、侵袭与FASN的过度表达可能有一定关系。2.在卵巢癌中,脂肪酸合成酶的表达可能与患者的年龄、肿瘤的分化程度、有无淋巴结转移及腹水细胞学检查无关,而与肿瘤的临床分期有关。3.FASN可以作为卵巢癌的早期诊断指标之一,它为卵巢癌的早期诊断提供新的依据,并对卵巢癌的恶性程度的临床分析及预后的监测有一定指导作用。
【Abstract】 BackgroundOvarian cancer is the most common of the three female genital cancer, and its incidence rate is second only to cervical cancer and uterine cancer. The mortality rate is relatively high. So far, according to domestic and foreign clinical data statistics, the five-year survival rate is only 25% -30%. The malignant behavior of tumor tissue is closely related to its specific material metabolism and energy metabolism. Fatty acid has an important role in cell metabolism, structure and function. Fatty acid synthase (FASN) is a key endogenous fatty acid synthesis enzyme, so in recent years studies on the expression of FASN in malignant tumors become one of the hotspot. In order to identify the early and effective diagnosis indicators of ovarian cancer, we study the expression of FASN in ovarian cancer and its clinical significance.ObjectiveTo study the expression of FASN in the normal ovarian tissue, benign ovarian tumors, borderline tumors, ovarian carcinoma, and its correlation with ovarian cancer, further to look for early diagnosis biological indicators.MethodsThe expressions of FASN in 13 normal ovarian tissues,13 benign ovarian tumors,13 cases of borderline tumors and 56 cases of ovarian cancer tissues were studied by Immunohistochemical method.Results1. FASN was not expressed in normal ovarian tissue, but largely expressed in benign ovarian tumors, borderline tumors and malignant tumors, and the positive expression rates were 15.4%,30.8%,67.1% respectively, showing a gradual upward trend.2. Compared with normal group, the expression of FASN in either malignant group or the junction group has a significant difference, and compared with either the benign group or the junction group, its expression in the malignant group was significant difference (P<0.05); while the comparison of the normal group with the benign group or the benign group compared with the junction group was not significant difference (P> 0.05).3. The expression level of FASN is not related to age, degree of differentiation, lymph node metastasis or ascites cytology, but highly related to the cancer clinical stages (P<0.05).4. The survival correlation analysis of ovarian cancer patients showed that compared to the negative expression group, the 3-year survival rate was significantly lower in the positive expression group (P<0.05).Conclusion1. The expression level of FASN in normal ovarian tissue, benign, borderline and malignant tumors showed gradual upward trend, suggesting that the occurrence of ovarian cancer, development and invasion may be related to the expression level of FASN.2. In ovarian cancer, the expression level of FASN may be not related to patient age, tumor differentiation, lymph node metastasis and ascites cytology, but highly related to the clinical stages of the tumor.3. FASN can be used as an indicator of early diagnosis of ovarian cancer, one of which is to provide early diagnosis of ovarian cancer, a new basis, and the degree of malignancy of ovarian cancer in clinical analysis and monitoring of certain prognostic guide.